Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Pulmatrix, Inc. (PULM)
Last pulmatrix, inc. earnings: 8/5 09:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.pulmatrix.com
Company Research
Source: Yahoo! Finance
rd amendment to Cipla partnership resulted in the wind down of the PUR1900 Phase 2b study and a significant reduction in expected cash burn for Pulmatrix Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix BEDFORD, Mass. March 28, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced fourth quarter and year-end financial results for 2023 and provided a corporate update on its development programs. Ted Raad , Chief Executive Officer of Pulmatrix, commented, "Winding down the Phase 2b study for PUR1900, along with other cost-savings measures, is expected to extend Pulmatrix's cash runwa
Show less
Read more
Impact Snapshot
Event Time:
PULM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PULM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PULM alerts
High impacting Pulmatrix, Inc. news events
Weekly update
A roundup of the hottest topics
PULM
News
- Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- 14-alpha Demethylase Inhibitors Drug Landscape Research Report 2024: Comprehensive Insights on 12+ Companies and 12+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
PULM
Sec Filings
- 3/28/24 - Form 424B3
- 3/28/24 - Form 10-K
- 3/28/24 - Form 8-K
- PULM's page on the SEC website